{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:51:14Z","timestamp":1760298674494,"version":"3.40.4"},"reference-count":22,"publisher":"Japan Atherosclerosis Society","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT"],"published-print":{"date-parts":[[2013]]},"DOI":"10.5551\/jat.13870","type":"journal-article","created":{"date-parts":[[2013,2,13]],"date-time":"2013-02-13T23:01:26Z","timestamp":1360796486000},"page":"472-480","source":"Crossref","is-referenced-by-count":1,"title":["Rationale, Design and Baseline Characteristics of a Study to Evaluate Effects of Candesartan on Cardiovascular Events after Drug-eluting Stent Implantation in Patients with Ischemic Heart Disease"],"prefix":"10.5551","volume":"20","author":[{"given":"Tomohiro","family":"Sakamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisao","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunichi","family":"Koide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyasu","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Shimomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichi","family":"Oshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Kikuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Oka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiko","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Morice MC, Serruys PW, Sousa JE, Fajadet J, Hayashi EB, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnàr F, Falotico R, the RAVEL Study Group: A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med, 2002; 346: 1773-1780","DOI":"10.1056\/NEJMoa012843"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O’ Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE, the SIRIUS Investigators: Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med, 2003; 349: 1315-1323","DOI":"10.1056\/NEJMoa035071"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Pfisterer M, et al. and BASKET-LATE Investigators: Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol, 2006; 48: 2584-2591","DOI":"10.1016\/j.jacc.2006.10.026"},{"key":"4","unstructured":"4) Spaulding C, Henry P, Teiger E, et al, for the TYPHOON Investigators: Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med, 2006; 355: 1093-1104 citation=5) Laarman GJ, Suttorp MJ, Dirksen MT, et al: Paclitaxeleluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med, 2006; 355: 1105-1113"},{"key":"5","doi-asserted-by":"crossref","unstructured":"6) Boden WE, O’ Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS; COURAGE Trial Research Group: Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med, 2007; 356: 1503-1516","DOI":"10.1056\/NEJMoa070829"},{"key":"6","doi-asserted-by":"crossref","unstructured":"7) Kim S, Iwao H: Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev, 2000; 52: 11-34","DOI":"10.1016\/S0031-6997(24)01434-0"},{"key":"7","doi-asserted-by":"crossref","unstructured":"8) Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H for the LIFE Study Group: Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE); a randomised trial against atenolol. Lancet, 2002; 359: 995-1003","DOI":"10.1016\/S0140-6736(02)08089-3"},{"key":"8","doi-asserted-by":"crossref","unstructured":"9) Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S for the CHARM investigators: Effects of candesartan on mortality and morbidity in patients with chronic heart failure; the CHARM-Overall programme. Lancet, 2003; 362: 759-766","DOI":"10.1016\/S0140-6736(03)14282-1"},{"key":"9","doi-asserted-by":"crossref","unstructured":"10) Mochizuki S, Dahlöf B, Shimizu M, Ikewaki K, Yoshikawa M, Taniguchi I, Ohta M, Yamada T, Ogawa K, Kanae K, Kawai M, Seki S, Okazaki F, Taniguchi M, Yoshida S, Tajima N for the Jikei Heart Study group: Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet, 2007; 369: 1431-1439","DOI":"10.1016\/S0140-6736(07)60669-2"},{"key":"10","doi-asserted-by":"crossref","unstructured":"11) Ogihara T, Nakao K, Fukui T, Fukiyama K, Ueshima K, Oba K, Sato T, Saruta T for the Candesartan Antihypertensive Survival Evaluation in Japan trial group: Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks. Candesartan antihypertensive survival evaluation in Japan trial. Hypertension, 2008; 51: 393-398","DOI":"10.1161\/HYPERTENSIONAHA.107.098475"},{"key":"11","doi-asserted-by":"crossref","unstructured":"12) Kasanuki H, Hagiwara N, Hosoda S, Sumiyoshi T, Honda T, Haze K, Nagashima M, Yamaguchi J, Origasa H, Urashima M, Ogawa H for the HIJ-CREATE investigators: Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). Eur Heart J, 2009; 30: 1203-1212","DOI":"10.1093\/eurheartj\/ehp101"},{"key":"12","doi-asserted-by":"crossref","unstructured":"13) Kondo J, Sone T, Tsuboi H, Mukawa H, Morishima I, Uesugi M, Kono T, Kosaka T, Yoshida T, Numaguchi Y, Matsui H, Murohara T, Okumura K: Effects of low-dose angiotensin II receptor blocker candesartan on cardiovascular events in patients with coronary artery disease. Am Heart J, 2003; 146: e20","DOI":"10.1016\/S0002-8703(03)00281-3"},{"key":"13","unstructured":"14) Peters S, Götting B, Trummel M, Rust H, Brattstrom A: Valsartan for prevention of restenosis after stenting of type B2\/C lesions: the VAL-PREST trial. J Invasive Cardiol, 2001; 13: 93-97"},{"key":"14","unstructured":"15) Japanese Society of Hypertension Guidelines Subcommittee for the Management of Hypertension. Guidelines for the Management of Hypertension (JSH 2004). Japanese Society of Hypertension: Tokyo, 2004 (in Japanese)"},{"key":"15","unstructured":"16) Japanese Society of Hypertension Guidelines Subcommittee for the Management of Hypertension. Guidelines for the Management of Hypertension (JSH 2009). Japanese Society of Hypertension: Tokyo, 2009 (in Japanese)"},{"key":"16","doi-asserted-by":"crossref","unstructured":"17) Tsunoda R, Sakamoto T, Kojima S, Ogata Y, Kitagwa A, Ogawa H: Recurrence of angina pectoris after percutaneous coronary intervention is reduced by statins in Japanese patients. J Cardiol, 2011; 58: 208-215","DOI":"10.1016\/j.jjcc.2011.07.002"},{"key":"17","unstructured":"18) Holm S: A simple sequentially rejective multiple test procedure. Scand J Stat, 1979; 6: 65-70"},{"key":"18","doi-asserted-by":"crossref","unstructured":"19) O’ Brien PC, Fleming TR: A multiple testing procedure for clinical trials. Biometrics, 1979; 35: 549-556 citation=20) Bangalore S, Kumar S, Wetterslev J, Messerli FH: Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials. BMJ, 2011; 342: d2234","DOI":"10.1136\/bmj.d2234"},{"key":"19","doi-asserted-by":"crossref","unstructured":"21) Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM for the Valsartan in Acute Myocardial Infarction Trial investigators: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med, 2003; 349: 1893-1906","DOI":"10.1056\/NEJMoa032292"},{"key":"20","doi-asserted-by":"crossref","unstructured":"22) ONTARGET investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med, 2008; 358: 1547-1559","DOI":"10.1056\/NEJMoa0801317"},{"key":"21","doi-asserted-by":"crossref","unstructured":"23) Kwon JS, Kim YS, Cho AS, Kim JS, Jeong SY, Hong MH, Jeong MH, Ahn Y: Origin of restenosis after drug-eluting stent implantation in hyperglycemia is inflammatory cells and thrombus. J Atheroscler Thromb, 2011; 18: 604-615","DOI":"10.5551\/jat.6965"},{"key":"22","doi-asserted-by":"crossref","unstructured":"24) Koh KK, Quon MJ, Han SH, Chung WJ, Lee Y, Shin EK: Anti-inflammatory and metabolic effects of candesartan in hypertensive patients. Int J Cardiol, 2006; 22; 108: 96-100","DOI":"10.1016\/j.ijcard.2005.07.040"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T21:14:41Z","timestamp":1745961281000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/20\/5\/20_13870\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.13870","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"type":"print","value":"1340-3478"},{"type":"electronic","value":"1880-3873"}],"subject":[],"published":{"date-parts":[[2013]]}}}